Cases & Deals

Celgene licenses to Cambrex certain chiral intermediate chemistries

Clients Celgene Corporation

Jones Day represented Celgene Corporation in its licensing to Cambrex of patents and technology related to the manufacture of certain chiral intermediate chemistries. The licensing was part of a settlement that concluded litigation initiated by Cambrex against Celgene for a dispute in connection with the sale of Celgene's chiral intermediate business to Cambrex in 1997 and litigation initiated by Celgene against Cambrex for patent infringement.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.